Bourel Michel, Ardaillou Raymond
Bull Acad Natl Med. 2004;188(8):1455-68.
Chronic renal failure represents a major problem of public health. Incidence for patients arrived at the terminal stage of the disease is in France 126.4/million inhabitants and the cost of medical care reaches 2 % of the expenses of the National Health Insurance. The progression of the disease is divided into 5 stages that are defined by the level of creatinine clearance from the stage of renal diseases with a normal renal function (clearance>90 ml/min) to the terminal stage (clearance <15 ml/min). Prevalence of patients at this ultimate stage is around 50,000. Prevalence for the totality of patients with a renal disease is evaluated between 2 and 3 millions. Renal diseases must be screened because they are silent and because an early pre-dialysis nephrological care allows renal replacement therapy to be delayed and the number of cardiovascular accidents to be diminished. Screening must be performed in the high-risk populations, essentially patients with diabetes, hypertension, coronary ischemia, renal tract diseases and all subjects treated with drugs toxic for the kidneys. Screening in the total population seems inadequate because of a high cost to benefit ratio. Screening is based on testing for the presence of proteinuria, quantifying the number of formed elements and plasma creatinine determination, the latter allowing, together with age and weight, glomerular filtration rate to be evaluated according to Cockcroft's formula. Prevention of renal diseases in the whole population necessitates the same life style as that recommended for prevention of cardiac and metabolic diseases. In the high-risk populations, one must control glycemia, blood pressure and cholesterol plasma level. In patients that have been already screened, renal function decay has to be slowed down by blocking the renin angiotensin system with converting enzyme inhibitors, controlling plasma cholesterol with statins and diminishing dietary proteins. In the light of these various data, the National Academy of medicine recommends: 1 - in the field of public health, to extend to the whole country the registries containing data on patients with terminal chronic renal failure, to support the creation of medical networks for the screening of renal diseases, to vaccine the patients against hepatitis B, flue and pneumococcal infections and to verify whether a low birth weight is associated with a greater risk of renal diseases in adulthood; 2 - in the field of teaching and research, to stop the decrease in the number of nephrologists, to promote research in genetics, to evaluate the efficacy of antifibrosis drugs and the possible renal toxicity of all new drugs.
慢性肾衰竭是一个重大的公共卫生问题。在法国,疾病终末期患者的发病率为每百万居民中有126.4人,医疗费用达到国民健康保险支出的2%。疾病进展分为5个阶段,根据肌酐清除率水平来定义,从肾功能正常的肾脏疾病阶段(清除率>90毫升/分钟)到终末期(清除率<15毫升/分钟)。处于这一终末期的患者患病率约为5万。肾病患者总数的患病率估计在200万至300万之间。必须对肾病进行筛查,因为它们症状不明显,而且早期透析前的肾病护理可延迟肾脏替代治疗并减少心血管意外的发生次数。筛查必须在高危人群中进行,主要是糖尿病患者、高血压患者、冠状动脉缺血患者、泌尿系统疾病患者以及所有接受对肾脏有毒性药物治疗的受试者。由于成本效益比高,对全体人群进行筛查似乎并不合适。筛查基于检测蛋白尿的存在、量化有形成分数量以及测定血浆肌酐,后者与年龄和体重一起,可根据Cockcroft公式评估肾小球滤过率。在全体人群中预防肾病需要与预防心脏和代谢疾病所推荐的相同生活方式。在高危人群中,必须控制血糖、血压和血浆胆固醇水平。对于已经接受筛查的患者,必须通过使用血管紧张素转换酶抑制剂阻断肾素 - 血管紧张素系统、用他汀类药物控制血浆胆固醇以及减少膳食蛋白质来减缓肾功能衰退。鉴于这些不同的数据,国家医学科学院建议:1 - 在公共卫生领域,将包含终末期慢性肾衰竭患者数据的登记系统扩展至全国,支持建立肾病筛查医疗网络,为患者接种乙肝、流感和肺炎球菌感染疫苗,并核实低出生体重是否与成年后患肾病的风险增加有关;2 - 在教学和研究领域,阻止肾病学家数量的减少,促进遗传学研究,评估抗纤维化药物的疗效以及所有新药可能的肾毒性。